Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.11 - Poster Session 1 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 45
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.11-019 - Phase 2 double-blind, placebo-controlled study of three-weekly farletuzumab with a platinum containing doublet in subjects with previously untreated folate receptor alpha (FRA) expressing non-small-cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): J.D. Maltzman
- Abstract
Loading... -
+
P1.11-037 - Phase II activity of the HSP90 inhibitor AUY922 in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): F. Barlesi
- Abstract
Loading... -
+
P1.11-046 - Women with lung cancer harboring epidermal growth factor (EGFR) mutations: prevalence, clinical characteristics and EGFR tyrosine kinase (TKI) treatment-related outcomes. Results from the Spanish WORLD07 database
09:30 - 09:30 | Author(s): E. Felip
- Abstract
Loading...
-
+
O03 - NSCLC - Targeted Therapies I
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:J. Ross
- Coordinates: 10/28/2013, 10:30 - 12:00, Bayside Auditorium B, Level 1
-
+
O03.01 - GALAXY-1: Randomized phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma: Results in biomarker sub-groups and all adenocarcinoma patients.
10:30 - 10:40 | Author(s): S.S. Ramalingam
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
O04 - Molecular Pathology I
- Type: Oral Abstract Session
- Track: Pathology
- Presentations: 8
- Moderators:I.I. Wistuba
- Coordinates: 10/28/2013, 10:30 - 12:00, Parkside Ballroom A, Level 1
-
+
O04.05 - Epidemiology of PI3K pathway alterations in patients with metastatic non-small cell lung cancer (NSCLC): findings from the international BASALT-1 study
11:15 - 11:25 | Author(s): G.K. Dy
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.06 - Poster Session 2 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 50
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.06-012 - Impact of EGFR T790M mutations and BIM mRNA expression on progression-free survival (PFS) and overall survival (OS) in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial
09:30 - 09:30 | Author(s): R. Rosell
- Abstract
Loading...
-
+
P2.11 - Poster Session 2 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 46
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.11-044 - Phase IB study to evaluate the efficacy and tolerability of Olaparib (AZD2281) plus Gefitinib in patients (P) with Epidermal Growth Factor Receptor (EGFR) mutation positive advanced Non-Small Cell Lung Cancer (NSCLC) patients (P). (NCT=1513174/GECP-GOAL)
09:30 - 09:30 | Author(s): R. Garcia Campelo
- Abstract
Loading...
-
+
P2.22 - Poster Session 2 - Epidemiology, Etiology
- Type: Poster Session
- Track: Prevention & Epidemiology
- Presentations: 13
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.22-008 - Analysis of family history of cancer in women with lung cancer (WLC) from the Spanish WORLD07 database
09:30 - 09:30 | Author(s): M. Majem
- Abstract
Loading...
-
+
O16 - NSCLC - Targeted Therapies III
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:H.A. Wakelee
- Coordinates: 10/29/2013, 10:30 - 12:00, Parkside Auditorium, Level 1
-
+
O16.03 - Cost-utility analysis of first-line treatment with erlotinib versus chemotherapy in EGFR-mutant advanced non-small-cell lung cancer (NSCLC): economic analysis of EURTAC trial
10:50 - 11:00 | Author(s): A. Vergnenegre
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MO18 - NSCLC - Targeted Therapies IV
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 13
- Moderators:L. Horn
- Coordinates: 10/29/2013, 16:15 - 17:45, Bayside Auditorium B, Level 1
-
+
MO18.01 - An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1)
16:15 - 16:20 | Author(s): L. Horn
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.02 - Poster Session 3 - Novel Cancer Genes and Pathways
- Type: Poster Session
- Track: Biology
- Presentations: 22
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.02-009 - ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer (NSCLC) patients with the EGFR T790M mutation
09:30 - 09:30 | Author(s): N. Karachaliou
- Abstract
Loading...
-
+
P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 53
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.06-006 - Integrated genomic analysis of EGFR-mutant non-small cell lung cancer immediately following erlotinib initiation in patients
09:30 - 09:30 | Author(s): P. Gianikopoulos
- Abstract
Loading...
